FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2275108515> ?p ?o ?g. }

• W2275108515 endingPage "2" @default.
• W2275108515 startingPage "1" @default.
• W2275108515 abstract "After more than two decades of research, the efforts to translate the concept of RNA based vaccination have reached a critical mass. Several preclinical and clinical projects located in the academic or industrial setting are underway and the coming years will allow us to get broad insight into clinical feasibility, safety, and first efficacy data. It can be anticipated that some RNA based vaccines will be approved within the near future.The use of in vitro transcribed RNA is now viewed as an attractive approach for vaccination therapies, with several features contributing to its favorable characteristics. RNA allows expression of molecularly well-defined proteins and its half-life can be steered through modifications in the RNA backbone. Moreover, unlike DNA, RNA does not need to enter the nucleus during transfection and there is no risk of integration into the genome, assuring safety through transient activity. Rapid design and synthesis in response to demand, accompanied by inexpensive pharmaceutical production, are additional features facilitating its clinical translation.The seminal work of Wolff et al. which showed that RNA injected directly into skeletal muscle can lead to protein expression opened the era of RNA based therapeutics [1]. This observation was followed by Martinon et al. and Conry et al. who performed the first vaccinations with viral- and cancer-antigen encoding RNA, respectively, and elicited antigen-specific immune responses [2, 3]. RNA based vaccination was also carried out by ex vivo transfection of mRNA into autologous dendritic cells (DCs) which was initially described by Boczkowski et al. [4]. Along with the introduction of highly efficient transfection methods for RNA [5], several preclinical and clinical studies showed the safety and efficacy of this RNA based vaccination strategy [6]. In a different setting, Hoerr et al. proved that direct injection of naked or protamine-protected RNA intradermally can lead to induction of T cell and antibody responses in preclinical models and then translated the approach into a clinical setting [7–10]. Personalized cancer vaccination with RNA and intravenous delivery of liposome-complexed RNA [11, 12] are other recent promising strategies that have reached the clinical stage. In addition to cancer, other disease settings such as infectious diseases as well as allergy were also shown to benefit from RNA based vaccination [13–15].In this special issue, a number of papers will illustrate and summarize the advances in this emerging field. M. A. McNamara et al. will provide a comprehensive review on RNA based vaccines in cancer immunotherapy, which is further detailed for the use of mutanome engineered RNA by M. Vormehr et al. These will be complemented by a review from K. K. L. Phua describing targeted delivery systems for RNA based nanoparticle tumor vaccines. Other contributions will describe RNA based methods for in vitro analytics such as cytotoxicity (T. A. Omokoko et al.) or effects of RNA on transcriptome of DCs (S. Hoyer et al.). Finally, E. Hattinger et al. will also demonstrate, with a different disease focus, the efficacy of prophylactic RNA vaccination against allergy.In conclusion, this special issue covers many aspects of RNA based vaccines. As RNA based vaccination is not the only application of the RNA technology (RNA based protein replacement, immunomodulation, and cellular therapy are further promising fields of development), we hope to have sparked the readers interest in RNA based therapies in general.Sebastian KreiterMustafa DikenSteve PascoloSmita K. NairKris M. ThielemansAndrew Geall" @default.
• W2275108515 created "2016-06-24" @default.
• W2275108515 creator A5003331131 @default.
• W2275108515 creator A5011084407 @default.
• W2275108515 creator A5051436334 @default.
• W2275108515 creator A5075569536 @default.
• W2275108515 creator A5077961362 @default.
• W2275108515 creator A5087903302 @default.
• W2275108515 date "2016-01-01" @default.
• W2275108515 modified "2023-09-23" @default.
• W2275108515 title "RNA Vaccination Therapy: Advances in an Emerging Field" @default.
• W2275108515 cites W1966322307 @default.
• W2275108515 cites W1971201276 @default.
• W2275108515 cites W1981552958 @default.
• W2275108515 cites W2014495927 @default.
• W2275108515 cites W2054298563 @default.
• W2275108515 cites W2063287711 @default.
• W2275108515 cites W2066847748 @default.
• W2275108515 cites W2079696222 @default.
• W2275108515 cites W2083958143 @default.
• W2275108515 cites W2104719439 @default.
• W2275108515 cites W2108706633 @default.
• W2275108515 cites W2135087025 @default.
• W2275108515 cites W2167614869 @default.
• W2275108515 cites W2168071482 @default.
• W2275108515 cites W2186068577 @default.
• W2275108515 cites W4241462697 @default.
• W2275108515 doi "https://doi.org/10.1155/2016/9703914" @default.
• W2275108515 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4785387" @default.
• W2275108515 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27019856" @default.
• W2275108515 hasPublicationYear "2016" @default.
• W2275108515 type Work @default.
• W2275108515 sameAs 2275108515 @default.
• W2275108515 citedByCount "6" @default.
• W2275108515 countsByYear W22751085152017 @default.
• W2275108515 countsByYear W22751085152018 @default.
• W2275108515 countsByYear W22751085152021 @default.
• W2275108515 countsByYear W22751085152023 @default.
• W2275108515 crossrefType "journal-article" @default.
• W2275108515 hasAuthorship W2275108515A5003331131 @default.
• W2275108515 hasAuthorship W2275108515A5011084407 @default.
• W2275108515 hasAuthorship W2275108515A5051436334 @default.
• W2275108515 hasAuthorship W2275108515A5075569536 @default.
• W2275108515 hasAuthorship W2275108515A5077961362 @default.
• W2275108515 hasAuthorship W2275108515A5087903302 @default.
• W2275108515 hasBestOaLocation W22751085151 @default.
• W2275108515 hasConcept C159047783 @default.
• W2275108515 hasConcept C202444582 @default.
• W2275108515 hasConcept C22070199 @default.
• W2275108515 hasConcept C33923547 @default.
• W2275108515 hasConcept C71924100 @default.
• W2275108515 hasConcept C9652623 @default.
• W2275108515 hasConceptScore W2275108515C159047783 @default.
• W2275108515 hasConceptScore W2275108515C202444582 @default.
• W2275108515 hasConceptScore W2275108515C22070199 @default.
• W2275108515 hasConceptScore W2275108515C33923547 @default.
• W2275108515 hasConceptScore W2275108515C71924100 @default.
• W2275108515 hasConceptScore W2275108515C9652623 @default.
• W2275108515 hasLocation W22751085151 @default.
• W2275108515 hasLocation W22751085152 @default.
• W2275108515 hasLocation W22751085153 @default.
• W2275108515 hasLocation W22751085154 @default.
• W2275108515 hasOpenAccess W2275108515 @default.
• W2275108515 hasPrimaryLocation W22751085151 @default.
• W2275108515 hasRelatedWork W1506200166 @default.
• W2275108515 hasRelatedWork W1995515455 @default.
• W2275108515 hasRelatedWork W2048182022 @default.
• W2275108515 hasRelatedWork W2080531066 @default.
• W2275108515 hasRelatedWork W2748952813 @default.
• W2275108515 hasRelatedWork W2899084033 @default.
• W2275108515 hasRelatedWork W3031052312 @default.
• W2275108515 hasRelatedWork W3032375762 @default.
• W2275108515 hasRelatedWork W3108674512 @default.
• W2275108515 hasRelatedWork W2181940165 @default.
• W2275108515 hasVolume "2016" @default.
• W2275108515 isParatext "false" @default.
• W2275108515 isRetracted "false" @default.
• W2275108515 magId "2275108515" @default.
• W2275108515 workType "article" @default.